EGFR/B7H3-ADC
/ GemPharmatech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
A novel EGFR and B7H3 dual-targeted antibody-drug conjugate (ADC) for the treatment of solid tumors
(AACR 2026)
- "our EGFR/B7H3-ADCs show potential therapeutic promise in patients with EGFR or B7H3 positive tumors. This study provides crucial rationale for supporting the further development of our novel dual-targeted Antibody-drug Conjugates (ADCs)."
ADC • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Head and Neck Cancer • Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CD276
1 to 1
Of
1
Go to page
1